Jaguar Health (NASDAQ: JAGX) stock is garnering attention following the appointment of a new Senior Vice President (SVP) of Growth Strategy.
Jaguar Health (JAGX) recently announced the appointment of Catherine Miller Collis, a seasoned professional with over two decades of experience in the biopharmaceutical sector, as Senior Vice President of Growth Strategy.
Her appointment comes at a crucial time as Jaguar Health prepares for the commercial launch of Gelclair, a protective gel for oral mucositis management—a common side effect of cancer treatments, and expands its focus to include cancer-related supportive care. Collis played a pivotal role in Jaguar’s recent in-licensing of Gelclair®.
The President and CEO of Jaguar, Lisa Conte, has voiced her confidence in the abilities of Collis, with a nod to her vast experience in commercial and business development. With Collis on board, Jaguar anticipates significant strides in advancing its growth strategy, particularly in the realm of cancer and gastrointestinal (GI) supportive care.
Collis has expressed her excitement about joining Jaguar and contributing to the company’s portfolio of FDA-approved prescription products. She emphasized the importance of providing cancer patients with supportive care products that offer soothing pain relief without numbing, underlining the focus on safety and effectiveness.
Jaguar Health is broadening its horizons to encompass care related to cancer, with Gelclair as a cornerstone of this plan. The firm is also on the edge of its seat for the outcomes of its crucial Phase 3 OnTarget trial of crofelemer for chemotherapy-induced overactive bowel (CIOB).
Before joining Jaguar, Collis held leadership roles in several companies, including Vibrant Gastro, Ironwood Pharmaceuticals, and Zealand Pharma (NASDAQ: ZEAL). Her extensive experience includes developing and commercializing therapies for GI disorders and diseases, along with a proven track record in creating and executing innovative commercial strategies.
Jaguar Health (NASDAQ: JAGX) Stock Price Action
At the time of publication, JAGX stock has traded at $0.18, marking a 7.40% increase from the previous trading session. Traders have exchanged 68,793,455 (68.79 million) shares, surpassing the average daily trading volume of 57.67 million.
